Turkish Journal of Gastroenterology
Gastrointestinal Tract - Original Article

Real world survival data of a rare malignancy: Anal cancer results in HIV negative patients from Turkey

1.

Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

2.

Department of Radiation Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

Turk J Gastroenterol 2018; 29: 411-418
DOI: 10.5152/tjg.2018.17660
Read: 393 Downloads: 159 Published: 25 July 2019

Abstract

Background/Aims: An organ preservation approach using chemoradiotherapy has been established for anal cancer. This retrospective cohort study aimed to define the clinico-demographic characteristics and outcomes of cases of human immunodeficiency virus (HIV)-negative anal carcinoma during a period of 20 years in a single comprehensive cancer institute.

Materials and Methods: This was a single-center retrospective cohort study of patients who were treated between January 1995 and January 2015. The primary outcome measures that were investigated included overall survival (OS), progression-free survival (PFS), colostomy rates, and colostomy-free survival (CFS).

Results: A total of 28 patients who were principally treated with standard 5-fluorouracil + mitomycin combination chemoradiotherapy were eligible for analysis. The 3- and 5-year PFS rates were 92.4% and 63%, respectively. The lower T stage was found to be associated with a prolonged PFS (p=0.001). The 3- and 5-year CFS rates were 84.3% and 74.9%, respectively. A longer CFS was observed with lower T stages (p=0.05). At the last follow-up, 75% of the patients with anal cancer were alive, and 71.4% of the patients were disease free. The median OS was not reached 

 

Cite this article as: Esin E, Yıldız F, Laçin Ş, et al. Real world survival data of a rare malignancy: Anal cancer results in HIV negative patients from Turkey. Turk J Gastroenterol 2018; 29: 411-8.

Files
EISSN 2148-5607